Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dare Bioscience (DARE) Change in Cash (2016 - 2025)

Dare Bioscience (DARE) has disclosed Change in Cash for 11 consecutive years, with $18.0 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Change in Cash rose 448.11% year-over-year to $18.0 million, compared with a TTM value of $11.8 million through Sep 2025, up 539.13%, and an annual FY2024 reading of $5.2 million, up 121.74% over the prior year.
  • Change in Cash was $18.0 million for Q3 2025 at Dare Bioscience, up from -$5.3 million in the prior quarter.
  • Across five years, Change in Cash topped out at $36.5 million in Q3 2021 and bottomed at -$14.8 million in Q1 2023.
  • Average Change in Cash over 5 years is $984515.5, with a median of -$3.4 million recorded in 2023.
  • The sharpest move saw Change in Cash skyrocketed 85601.28% in 2021, then plummeted 1016.71% in 2024.
  • Year by year, Change in Cash stood at $6.1 million in 2021, then crashed by 193.72% to -$5.7 million in 2022, then skyrocketed by 40.24% to -$3.4 million in 2023, then skyrocketed by 230.63% to $4.5 million in 2024, then soared by 303.99% to $18.0 million in 2025.
  • Business Quant data shows Change in Cash for DARE at $18.0 million in Q3 2025, -$5.3 million in Q2 2025, and -$5.4 million in Q1 2025.